Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Operating Expenses data on file, last reported at $29.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 47.32% year-over-year to $29.7 million; the trailing twelve-month figure through Dec 2025 stood at $176.5 million (down 17.67% YoY), and the FY2025 full-year result was $176.5 million, down 17.67% from the prior year.
• Operating Expenses for Q4 2025 stood at $29.7 million, roughly flat from $29.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $59.2 million in Q1 2025 and bottomed at $15.6 million in Q2 2021.
• The 5-year median for Operating Expenses is $35.4 million (2022), against an average of $37.6 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 96.46%; it then plunged 49.79% in 2025.
• A 5-year view of Operating Expenses shows it stood at $24.9 million in 2021, then climbed by 28.53% to $32.0 million in 2022, then jumped by 45.8% to $46.6 million in 2023, then rose by 20.81% to $56.3 million in 2024, then tumbled by 47.32% to $29.7 million in 2025.
• The last three Operating Expenses figures came in at $29.7 million (Q4 2025), $29.6 million (Q3 2025), and $58.0 million (Q2 2025), per Business Quant data.

Peer Comparison